GlassScriptPhysician profile
Patrick G Pilie
NPI 1174818181
$30,270.54
in general payments reported to CMS, 2019-2025
19 companies · $7,609 in 2025
The $7,609 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $773 · 2021: $3,210 · 2022: $11K · 2023: $2,961 · 2024: $4,258 · 2025: $7,609.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,603 · Food and Beverage: $3,094 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,450 · Travel and Lodging: $682.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,602.50 |
| Food and Beverage | $3,093.69 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,450.00 |
| Travel and Lodging | $681.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $8,128.52 | 2022-2025 | |
| Dendreon Pharmaceuticals LLC | $5,033.01 | 2021-2025 | Provenge |
| Janssen Scientific Affairs, LLC | $3,931.27 | 2022-2025 | Erleada, Akeega |
| Astrazeneca Uk Limited | $3,350.00 | 2025 | Lynparza |
| Pfizer INC. | $3,162.29 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $2,736.45 | 2019-2025 | Truqap, Lynparza |
| Janssen Biotech, INC. | $2,522.29 | 2019-2025 | Erleada, Balversa, Akeega |
| Genzyme Corporation | $666.92 | 2019 | |
| Exelixis INC. | $490.23 | 2023-2025 | Cabometyx |
| Eisai INC. | $45.70 | 2023-2024 | |
| Sumitomo Pharma America, INC. | $33.23 | 2024 | Orgovyx |
| Sun Pharmaceutical Industries INC. | $31.74 | 2023-2024 | Yonsa |
| Pharmaand Gmbh | $26.94 | 2025 | Rubraca |
| Tolmar, INC. | $26.94 | 2025 | Eligard, Rubraca |
| Abbvie INC. | $25.09 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $24.89 | 2024 | Lynparza |
| Aveo Pharmaceuticals, INC. | $21.61 | 2025 | |
| Astellas Pharma US INC | $13.42 | 2024 | Xtandi |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Pilie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.